Novartis AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public, Private
- Established
- 1996-01-01
- Employees
- 76K
- Market Cap
- $242.6B
- Introduction
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
A Crossover Study to Determine the Effect on Lung Function of Indacaterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD), Using Tiotropium as an Active Control
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- First Posted Date
- 2008-02-14
- Last Posted Date
- 2011-08-17
- Lead Sponsor
- Novartis
- Target Recruit Count
- 169
- Registration Number
- NCT00615459
- Locations
- 🇪🇸
Novartis Investigator Site, Orense, Spain
🇪🇸Novartis Investigative Site, Madrid, Spain
🇪🇸Novartis Investigative site, Alicante, Spain
Safety, Tolerability, and Efficacy of AEB071 in the Treatment of Uveitis
- First Posted Date
- 2008-02-14
- Last Posted Date
- 2020-12-22
- Lead Sponsor
- Novartis
- Target Recruit Count
- 13
- Registration Number
- NCT00615693
- Locations
- 🇺🇸
University of Southern California Doheny Eye Institute, Los Angeles, California, United States
🇺🇸John Hopkins Hospital/Wilmer Eye Institute, Baltimore, Maryland, United States
🇺🇸University of California, San Francisco, California, United States
Efficacy and Safety of Telbivudine in Patients With Chronic Hepatitis B
- First Posted Date
- 2008-02-01
- Last Posted Date
- 2012-05-02
- Lead Sponsor
- Novartis
- Registration Number
- NCT00606099
- Locations
- 🇺🇸
Novartis, Sterling, Virginia, United States
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACZ885 in Patients With Type 2 Diabetes
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2008-01-31
- Last Posted Date
- 2012-02-13
- Lead Sponsor
- Novartis
- Target Recruit Count
- 231
- Registration Number
- NCT00605475
- Locations
- 🇺🇸
Allied Research International - Cetero Research Miami, Miami, Florida, United States
🇺🇸Elite Research Institute Miami, Miami, Florida, United States
🇷🇺Novartis Investigative Site, St. Petersberg, Russian Federation
Safety and Tolerability of Indacaterol Maleate/Mometasone Furoate Delivered Via the Twisthaler® Device After 14 Days Treatment in Patients With Mild to Moderate Asthma
- Conditions
- Asthma
- Interventions
- Drug: placebo to indacaterol maleate/mometasone furoate
- First Posted Date
- 2008-01-31
- Last Posted Date
- 2013-04-22
- Lead Sponsor
- Novartis
- Target Recruit Count
- 28
- Registration Number
- NCT00605306
- Locations
- 🇫🇷
Novartis Investigator Site, Poitiers, France
Safety and Efficacy of QAX576 in Adults With Moderate Persistent Allergic Asthma
- First Posted Date
- 2008-01-18
- Last Posted Date
- 2016-03-04
- Lead Sponsor
- Novartis
- Registration Number
- NCT00598104
An Exploratory Study of the Effects of a Single Dose of QAX576 (an Interleukin-13 Monoclonal Antibody) on Simulated Hayfever
- First Posted Date
- 2008-01-02
- Last Posted Date
- 2017-02-24
- Lead Sponsor
- Novartis
- Target Recruit Count
- 36
- Registration Number
- NCT00584584
- Locations
- 🇬🇧
Novartis Investigator Site, London, United Kingdom
Feasibility and Reproducibility of Barostat Assessments of Colorectal Sensation During Colorectal Distention and Its Pharmacological Modulation Using Octreotide
- Conditions
- Irritable Bowel Syndrome (IBS)
- Interventions
- Drug: SMS995Drug: Placebo
- First Posted Date
- 2008-01-02
- Last Posted Date
- 2009-05-08
- Lead Sponsor
- Novartis
- Target Recruit Count
- 50
- Registration Number
- NCT00584298
- Locations
- 🇬🇧
Novartis Investigator Site, Nottingham, United Kingdom
Safety and Efficacy of Multiple Doses of Canakinumab (ACZ885) in Chronic Obstructive Pulmonary Disease (COPD) Patients
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2007-12-28
- Last Posted Date
- 2011-06-30
- Lead Sponsor
- Novartis
- Target Recruit Count
- 147
- Registration Number
- NCT00581945
- Locations
- 🇺🇸
Novartis Investigator Site, Richmond, Virginia, United States
Efficacy and Safety of AFQ056 in Reducing L-dopa Induced Dyskinesias in Parkinson's Disease Patients, and Safety in Combination With L-dopa
- First Posted Date
- 2007-12-28
- Last Posted Date
- 2010-05-14
- Lead Sponsor
- Novartis
- Target Recruit Count
- 31
- Registration Number
- NCT00582673
- Locations
- 🇩🇪
Novartis Investigator Site, Tuebingen, Germany